睿知中国疾病研究地图
候选清单0

正在招募胃癌I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid Tumors

ClinicalTrials.gov 上登记的一项胃癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心皖南医科大学第一附属医院First Affiliated Hospital of Wannan Medical College芜湖医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06126406,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Advanced, metastatic or recurrent malignant tumors diagnosed by histology or pathology, mainly colorectal cancer, esophageal cancer, gastric cancer, and pancreatic cancer;

    入选标准第 2 条

  3. Received the following anti-tumor treatments before screening: Received chemotherapy, targeted therapy or other experimental drug treatments within 14 days or at least 5 half-lives (whichever is shorter);

    排除标准第 4 条

    Except for alopecia or peripheral neuropathy, the toxicity of previous anti-tumor therapy has not improved to the baseline level or ≤ grade 1;

    排除标准第 8 条

  4. ECOG score 0-2 points;

    入选标准第 6 条

  5. Blood routine: white blood cells>3.0×10\^9/L,neutrophils>0.8×10\^9/L, lymphocytes cells>0.5×10\^9/L,platelets>75×10\^9/L, hemoglobin>80g/L;

    入选标准第 9 条

    Renal function: serum creatinine≤2.0×ULN;

    入选标准第 11 条

    Liver function: ALT and AST ≤3.0×ULN (for patients with liver tumor infiltration, it can be relaxed to ≤5.0×ULN);

    入选标准第 12 条

    Total bilirubin≤3.0×ULN;

    入选标准第 13 条

  6. At least one assessable lesion according to RECIST 1.1 criteria,For extranodal lesions, the length and diameter should be ≥10mm. For nodular lesions, the short diameter of the lymph node should be ≥15mm;

    入选标准第 5 条

  7. Suffering from other uncured malignant tumors in the past 3 years or at the same time, except cervical carcinoma in situ and basal cell carcinoma of the skin;

    排除标准第 15 条

    Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer test is greater than the normal range; hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C Virus (HCV) RNA test is greater than the normal range; human immunodeficiency virus (HIV) antibody positive; syphilis test positive;

    排除标准第 16 条

  8. Subjects agree to use reliable and effective contraceptive methods for contraception within 1 year after signing the informed consent form to receiving CAR-T cell infusion (excluding rhythm contraception);

    入选标准第 16 条

    Women who are pregnant or breastfeeding;

    排除标准第 17 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06126406,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age ≥18 years old, male or female;
  2. Advanced, metastatic or recurrent malignant tumors diagnosed by histology or pathology, mainly colorectal cancer, esophageal cancer, gastric cancer, and pancreatic cancer;
  3. After receiving at least second-line standard treatment failure (disease progression or intolerance, such as surgery, chemotherapy, radiotherapy, etc.) or lack of effective treatment methods;
  4. Immunohistochemical staining of tumor samples within 3 months confirmed that the tumor was CEA positive (clear membrane staining, positive rate ≥ 10%); , the positive rate ≥ 10%), the serum CEA of the patient is required to exceed 10ug/L.
  5. At least one assessable lesion according to RECIST 1.1 criteria,For extranodal lesions, the length and diameter should be ≥10mm. For nodular lesions, the short diameter of the lymph node should be ≥15mm;
  6. ECOG score 0-2 points;
  7. No serious mental disorder;
  8. Unless otherwise specified, the function of the vital organs of the subject shall meet the following conditions:
  9. Blood routine: white blood cells>3.0×10\^9/L,neutrophils>0.8×10\^9/L, lymphocytes cells>0.5×10\^9/L,platelets>75×10\^9/L, hemoglobin>80g/L;
  10. Cardiac function: echocardiography showed cardiac ejection fraction ≥50%, and no obvious abnormality was found on electrocardiogram;
  11. Renal function: serum creatinine≤2.0×ULN;
  12. Liver function: ALT and AST ≤3.0×ULN (for patients with liver tumor infiltration, it can be relaxed to ≤5.0×ULN);
  13. Total bilirubin≤3.0×ULN;
  14. Oxygen saturation ≥95% in non-oxygen state.
  15. Have apheresis or venous blood collection standards, and have no other contraindications for cell collection;
  16. Subjects agree to use reliable and effective contraceptive methods for contraception within 1 year after signing the informed consent form to receiving CAR-T cell infusion (excluding rhythm contraception);
  17. The patients themselves or their guardians agree to participate in this clinical trial and sign the ICF, indicating that they understand the purpose and procedures of this clinical trial and are willing to participate in the research.

排除标准:Exclusion Criteria:

  1. Those who have central nervous system metastasis or meningeal metastasis at the time of screening are judged by the investigator to be unsuitable for inclusion;
  2. Participated in other clinical studies within 1 month before screening;
  3. vaccinated with live attenuated vaccine within 4 weeks before screening;
  4. Received the following anti-tumor treatments before screening: Received chemotherapy, targeted therapy or other experimental drug treatments within 14 days or at least 5 half-lives (whichever is shorter);
  5. Active infection or uncontrollable infection requiring systemic treatment;
  6. Patients with intestinal obstruction, active gastrointestinal bleeding, or a history of gastrointestinal bleeding within 3 months;
  7. There is a large amount of uncontrolled fluid accumulation in the serous cavity;
  8. Except for alopecia or peripheral neuropathy, the toxicity of previous anti-tumor therapy has not improved to the baseline level or ≤ grade 1;
  9. Suffering from any of the following heart diseases:
  10. New York Heart Association (NYHA) stage III or IV congestive heart failure;
  11. Myocardial infarction or coronary artery bypass grafting (CABG) within 6 months before enrollment;
  12. Clinically significant ventricular arrhythmia, or a history of unexplained syncope (except those caused by vasovagal or dehydration);
  13. History of severe non-ischemic cardiomyopathy;
  14. Patients with active autoimmune disease, or other patients requiring long-term immunosuppressive therapy;
  15. Suffering from other uncured malignant tumors in the past 3 years or at the same time, except cervical carcinoma in situ and basal cell carcinoma of the skin;
  16. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer test is greater than the normal range; hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C Virus (HCV) RNA test is greater than the normal range; human immunodeficiency virus (HIV) antibody positive; syphilis test positive;
  17. Women who are pregnant or breastfeeding;
  18. Other investigators deem it unsuitable to participate in the research.

引自 ClinicalTrials.gov, NCT06126406, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06126406,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06126406